Revenue

Vanda Pharmaceuticals submits its novel GPP therapy, imsidolimab, for FDA review, offering new hope for patients and bolstering its rare disease portfolio.

The crypto giant reports massive growth, but a pivot to AI, operational fires, and rising debt reveal a risky strategy to reshape global computing power.

As New Jersey's cannabis market booms, Grown Rogue's one-year success reveals a potent strategy for blending craft quality with low-cost execution.

JCDecaux's new AI measures MTR audiences with precision, but can it win public trust by balancing data insights with total anonymity?

A complex share buyback and reverse stock split reveal Havas's deeper strategy: shoring up its finances to invest in a new era of health communication.

Radisson Hotel Group and SMHCC ink a deal for three new hotels, a strategic move to dominate the MICE market and capitalize on the Philippines' resurgence.

A moving company hosts a governor, revealing the complex logistics and infrastructure network profiting from America's massive wealth redistribution.

A new AI system deters birds to prevent avian flu. But its real innovation lies in data, transforming biosecurity from a costly chore into a profitable investment.

Canada’s condo market is in transition. With prices down and inventory up, a unique opportunity emerges for buyers before a projected 2027 recovery.

Palantir's DGSI contract renewal isn't just a deal; it's a story of strategic reliance, political tension, and the bedrock of its business model.

As Sinch appoints Lindy Puttkammer as its new CHRO, the move signals a deep focus on integrating its global workforce and nurturing talent from within.

EfTEN United Property Fund's soaring profits, fueled by a key housing project, highlight a strategic success story amid a recovering Baltic property market.

California's Movandi is moving to Riyadh. A look at how sovereign incentives are building a new semiconductor hub and the wireless backbone for an AI future.

Coldwell Banker India appoints a decade-long partner as Area Developer for four southern states, a strategic move to dominate the region's booming market.

FDA greenlights the first precision therapy for BRCA2-mutated mCSPC, a highly aggressive prostate cancer, slashing progression risk by 54%.

The infrastructure giant's new €800M share repurchase isn't just for shareholder value; it's a strategic move to fund future growth and acquisitions.

The junior explorer is expanding its footprint in a hot gold district. We analyze the financial mechanics, shareholder impact, and leadership incentives.

Beyond the runway hype, AI is now a core driver of commerce. But does it level the playing field or just raise the stakes for everyone involved?

The media giant is refinancing high-cost debt to fund acquisitions and tech. Is this a savvy move to secure its future or a risky balance sheet gamble?

Beyond a simple date change for its $10M dividend, Dominari Holdings is signaling a major strategic shift, funded by investment gains and aimed at AI.